Multivalent FAPI-based radiopharmaceuticals in PET/CT: from cancer diagnostics to theranostics

Radiopharmaceuticals targeting fibroblast activation protein (FAP) have rapidly emerged as innovative agents for cancer imaging and therapy. By selectively binding to cancer-associated fibroblasts (CAFs), radiolabeled FAP inhibitors (FAPIs) enable high-contrast PET/CT imaging across diverse tumor types. This article highlights recent advances in FAPI PET/CT imaging, with particular focus on the influence of multivalency effect in radiotracer development.